Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity

Executive Summary

Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.

You may also be interested in...



Wegovy Starting Doses Restrictions Will Continue Through The Year

Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.

Obesity Advocates Meet With FDA Commissioner, Push On Difference vs. Short-Term Weight-Loss

Groups discuss need for chronic care of the condition as well as the importance of having all drugs for all conditions adequately labeled for patients at higher body weights.

Can New Generation GLP-1s Overcome The Adherence Hurdle?

Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel